Pulse Biosciences (PLSE) Competitors

Pulse Biosciences logo
$45.55 +1.14 (+2.57%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$45.50 -0.04 (-0.10%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PLSE vs. GKOS, BAX, SNN, PEN, and PODD

Should you buy Pulse Biosciences stock or one of its competitors? Pulse Biosciences's main competitors and comparable companies include Glaukos (GKOS), Baxter International (BAX), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Insulet (PODD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulse Biosciences compare to Glaukos?

Pulse Biosciences (NASDAQ:PLSE) and Glaukos (NYSE:GKOS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

Pulse Biosciences has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K9,572.01-$72.78M-$1.21N/A
Glaukos$507.44M27.68-$187.69M-$2.94N/A

Glaukos has a net margin of -24.60% compared to Pulse Biosciences' net margin of -5,603.88%. Glaukos' return on equity of -0.97% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Glaukos -24.60%-0.97%-0.71%

Pulse Biosciences presently has a consensus target price of $66.60, suggesting a potential upside of 46.21%. Glaukos has a consensus target price of $218.00, suggesting a potential downside of 8.11%. Given Pulse Biosciences' higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Glaukos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Glaukos
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Pulse Biosciences has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

In the previous week, Glaukos had 27 more articles in the media than Pulse Biosciences. MarketBeat recorded 32 mentions for Glaukos and 5 mentions for Pulse Biosciences. Glaukos' average media sentiment score of 0.91 beat Pulse Biosciences' score of 0.63 indicating that Glaukos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Glaukos
11 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Glaukos beats Pulse Biosciences on 9 of the 15 factors compared between the two stocks.

How does Pulse Biosciences compare to Baxter International?

Pulse Biosciences (NASDAQ:PLSE) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Pulse Biosciences currently has a consensus price target of $66.60, indicating a potential upside of 46.21%. Baxter International has a consensus price target of $23.27, indicating a potential downside of 8.30%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Pulse Biosciences is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Baxter International
3 Sell rating(s)
10 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86

Pulse Biosciences has higher earnings, but lower revenue than Baxter International. Pulse Biosciences is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K9,572.01-$72.78M-$1.21N/A
Baxter International$11.24B1.17-$957M-$1.41N/A

In the previous week, Baxter International had 3 more articles in the media than Pulse Biosciences. MarketBeat recorded 8 mentions for Baxter International and 5 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.63 beat Baxter International's score of 0.62 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pulse Biosciences has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 0.2% of Baxter International shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Baxter International has a net margin of -6.23% compared to Pulse Biosciences' net margin of -5,603.88%. Baxter International's return on equity of 16.23% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Baxter International -6.23%16.23%5.08%

Summary

Pulse Biosciences beats Baxter International on 10 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Pulse Biosciences (NASDAQ:PLSE) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pulse Biosciences has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Smith & Nephew SNATS has a net margin of 0.00% compared to Pulse Biosciences' net margin of -5,603.88%. Smith & Nephew SNATS's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Smith & Nephew SNATS N/A N/A N/A

In the previous week, Pulse Biosciences had 1 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 5 mentions for Pulse Biosciences and 4 mentions for Smith & Nephew SNATS. Pulse Biosciences' average media sentiment score of 0.63 beat Smith & Nephew SNATS's score of 0.33 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Smith & Nephew SNATS
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pulse Biosciences currently has a consensus price target of $66.60, indicating a potential upside of 46.21%. Smith & Nephew SNATS has a consensus price target of $31.91, indicating a potential upside of 6.99%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Pulse Biosciences is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Smith & Nephew SNATS
2 Sell rating(s)
8 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.91

Smith & Nephew SNATS has higher revenue and earnings than Pulse Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K9,572.01-$72.78M-$1.21N/A
Smith & Nephew SNATS$6.16B2.03$625MN/AN/A

Summary

Pulse Biosciences beats Smith & Nephew SNATS on 10 of the 15 factors compared between the two stocks.

How does Pulse Biosciences compare to Penumbra?

Pulse Biosciences (NASDAQ:PLSE) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Penumbra has a net margin of 10.06% compared to Pulse Biosciences' net margin of -5,603.88%. Penumbra's return on equity of 10.39% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Pulse Biosciences-5,603.88% -77.88% -67.89%
Penumbra 10.06%10.39%8.09%

Pulse Biosciences has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Penumbra has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulse Biosciences$350K9,572.01-$72.78M-$1.21N/A
Penumbra$1.40B8.96$177.69M$3.9780.38

In the previous week, Pulse Biosciences had 1 more articles in the media than Penumbra. MarketBeat recorded 5 mentions for Pulse Biosciences and 4 mentions for Penumbra. Pulse Biosciences' average media sentiment score of 0.63 beat Penumbra's score of -0.02 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Penumbra
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pulse Biosciences currently has a consensus price target of $66.60, indicating a potential upside of 46.21%. Penumbra has a consensus price target of $367.07, indicating a potential upside of 15.02%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pulse Biosciences is more favorable than Penumbra.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Penumbra
0 Sell rating(s)
14 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.18

Summary

Pulse Biosciences beats Penumbra on 9 of the 16 factors compared between the two stocks.

How does Pulse Biosciences compare to Insulet?

Insulet (NASDAQ:PODD) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Insulet has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Insulet has a net margin of 13.44% compared to Pulse Biosciences' net margin of -5,603.88%. Insulet's return on equity of 31.76% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet13.44% 31.76% 14.48%
Pulse Biosciences -5,603.88%-77.88%-67.89%

In the previous week, Insulet had 13 more articles in the media than Pulse Biosciences. MarketBeat recorded 18 mentions for Insulet and 5 mentions for Pulse Biosciences. Pulse Biosciences' average media sentiment score of 0.63 beat Insulet's score of 0.35 indicating that Pulse Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
4 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pulse Biosciences
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.0% of Pulse Biosciences shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Insulet presently has a consensus price target of $184.33, suggesting a potential upside of 38.42%. Pulse Biosciences has a consensus price target of $66.60, suggesting a potential upside of 46.21%. Given Pulse Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Pulse Biosciences is more favorable than Insulet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
1 Sell rating(s)
13 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.46
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Insulet has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.41$247.10M$6.1421.69
Pulse Biosciences$350K9,572.01-$72.78M-$1.21N/A

Summary

Insulet beats Pulse Biosciences on 8 of the 15 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLSE vs. The Competition

MetricPulse BiosciencesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.41B$6.00B$7.76B$11.71B
Dividend YieldN/A1.69%2.47%4.67%
P/E Ratio-37.6438.2132.5328.82
Price / Sales9,572.015.458.115.41
Price / CashN/A23.7921.0521.90
Price / Book18.224.014.263.50
Net Income-$72.78M$143.06M$3.51B$394.12M
1 Month Performance-11.23%-8.30%-10.58%-12.04%
1 Year Performance250.12%-4.45%-4.78%-11.42%

Pulse Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLSE
Pulse Biosciences
3.5238 of 5 stars
$45.55
+2.6%
$66.60
+46.2%
+259.8%$3.41B$350KN/A116
GKOS
Glaukos
2.7147 of 5 stars
$236.81
-0.8%
$216.71
-8.5%
+149.0%$14.13B$507.44MN/A1,094
BAX
Baxter International
1.5085 of 5 stars
$26.42
+0.0%
$23.27
-11.9%
+45.6%$13.66B$11.24B13.6137,500
SNN
Smith & Nephew SNATS
1.8562 of 5 stars
$30.95
-0.3%
$31.91
+3.1%
-6.8%$13.00B$6.16BN/A16,988
PEN
Penumbra
1.7649 of 5 stars
$321.47
-0.1%
$367.07
+14.2%
+14.0%$12.69B$1.40B81.484,700

Related Companies and Tools


This page (NASDAQ:PLSE) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners